Avonex does not slow progression of disability

A board to discuss the Multiple Sclerosis modifying drug Avonex

Avonex does not slow progression of disability

Postby NHE » Wed Sep 05, 2018 10:33 pm

Interferon β for secondary progressive multiple sclerosis: a systematic review.
J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):420-6.

    BACKGROUND: It is unclear whether recombinant β interferons (IFNβ) can be effective in secondary progressive multiple sclerosis (SPMS). The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS.

    METHODS: Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995-March 2012).

    RESULTS: 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95% CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events.

    CONCLUSION: 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.
User avatar
NHE
Volunteer Moderator
 
Posts: 4892
Joined: Sat Nov 20, 2004 4:00 pm

Advertisement

Return to Avonex

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service